OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

OncoVent Co., Ltd., a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., yesterday entered into a license agreement with Orient EuroPharma Co., Ltd..